BioCentury | Dec 8, 2011
Cover Story

Big MAC attack in osteoarthritis

...Ergidina , a recombinant human minibody against C5 fused with an arginine-glycine-aspartic acid motif, from Adienne Pharma & Biotech...
BioCentury | Oct 4, 2010
Clinical News

Begedina regulatory update

...The COMP issued a positive opinion to grant Orphan Drug designation for Adienne's Begedina to treat...
...CD26 antigen of hematopoietic progenitor cells. COMP is part of the European Medicines Agency (EMA). Adienne Pharma & Biotech...
BioCentury | Mar 29, 2010
Clinical News

Tepadina thiotepa regulatory update

...The European Medicines Agency (EMA) approved an MAA from Adienne for Tepadina thiotepa as a conditioning...
...progenitor cell transplantation. The alkylating agent has Orphan status for the indication in the EU. Adienne...
...distribution rights in certain European countries, plans to launch the product in Germany next quarter. Adienne Pharma & Biotech...
BioCentury | Jan 4, 2010
Clinical News

Tepadina thiotepa regulatory update

...EMEA's CHMP issued a positive opinion on an MAA from Adienne for Tepadina thiotepa as a...
...adult and pediatric patients. The product has Orphan designation for the indication in the EU. Adienne Pharma & Biotech...
BioCentury | Nov 24, 2008
Clinical News

Recombinant human minibody against complement component C5 fused with RGD-motif regulatory update

...for Orphan Medical Products (COMP) issued a positive opinion to grant Orphan Drug designation for Adienne's...
...complement component C5 fused with RGD-motif to prevent ischemia/reperfusion injury associated with solid organ transplantation. Adienne Pharma & Biotech...
BioCentury | Jul 21, 2008
Clinical News

Mubodina regulatory update

...for Orphan Medical Products (COMP) issued a positive opinion to grant Orphan Drug designation for Adienne's...
...aHUS). The recombinant human minibody C5 complement component is in preclinical development for the indication. Adienne...
Items per page:
1 - 6 of 6
BioCentury | Dec 8, 2011
Cover Story

Big MAC attack in osteoarthritis

...Ergidina , a recombinant human minibody against C5 fused with an arginine-glycine-aspartic acid motif, from Adienne Pharma & Biotech...
BioCentury | Oct 4, 2010
Clinical News

Begedina regulatory update

...The COMP issued a positive opinion to grant Orphan Drug designation for Adienne's Begedina to treat...
...CD26 antigen of hematopoietic progenitor cells. COMP is part of the European Medicines Agency (EMA). Adienne Pharma & Biotech...
BioCentury | Mar 29, 2010
Clinical News

Tepadina thiotepa regulatory update

...The European Medicines Agency (EMA) approved an MAA from Adienne for Tepadina thiotepa as a conditioning...
...progenitor cell transplantation. The alkylating agent has Orphan status for the indication in the EU. Adienne...
...distribution rights in certain European countries, plans to launch the product in Germany next quarter. Adienne Pharma & Biotech...
BioCentury | Jan 4, 2010
Clinical News

Tepadina thiotepa regulatory update

...EMEA's CHMP issued a positive opinion on an MAA from Adienne for Tepadina thiotepa as a...
...adult and pediatric patients. The product has Orphan designation for the indication in the EU. Adienne Pharma & Biotech...
BioCentury | Nov 24, 2008
Clinical News

Recombinant human minibody against complement component C5 fused with RGD-motif regulatory update

...for Orphan Medical Products (COMP) issued a positive opinion to grant Orphan Drug designation for Adienne's...
...complement component C5 fused with RGD-motif to prevent ischemia/reperfusion injury associated with solid organ transplantation. Adienne Pharma & Biotech...
BioCentury | Jul 21, 2008
Clinical News

Mubodina regulatory update

...for Orphan Medical Products (COMP) issued a positive opinion to grant Orphan Drug designation for Adienne's...
...aHUS). The recombinant human minibody C5 complement component is in preclinical development for the indication. Adienne...
Items per page:
1 - 6 of 6